查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595275

周邊動脈疾病治療藥物市場：按治療類型、適應症階段和最終用戶分類 - 全球預測 2025-2030

Peripheral Arterial Disease Therapeutics Market by Treatment Type (Medications, Surgical Treatments), Indication Stage (Asymptomatic, Ischemic Rest Pain, Mild Claudication), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

周邊動脈疾病藥物市場2023年估值為47.5億美元，預計2024年將達到51.4億美元，複合年成長率為8.73%，到2030年將達到85.5億美元。

周邊動脈疾病(PAD) 治療市場的範圍和定義包括 PAD 的診斷、治療和管理。 PAD 是一種因動脈狹窄而導致四肢血流減少的疾病。對有效 PAD 治療的需求源自於糖尿病、高血壓和肥胖等危險因子的日益普及。應用領域包括藥品（抗血小板藥物、他汀類藥物等）、醫療設備（支架、血管成形術球囊）和旨在改善患者治療效果的生活型態管理計畫。最終使用領域主要包括醫院、專科診所和居家醫療環境。根據市場洞察，推動成長的關鍵因素包括微創治療的進步、人們對周邊動脈疾病（PAD）認知的提高以及易患血管疾病的老年人口迅速增加。最近的機會包括藥物釋放型技術、生技藥品和提供醫療干預和數位患者監測的全面醫療保健解決方案的開發。為了利用這些機會，公司應專注於個人化醫療的研發投資，並與高科技公司合作開發數位健康解決方案。儘管成長前景廣闊，但該市場仍面臨一些限制，例如先進治療的高成本、監管障礙以及患者對治療方法依從性的挑戰。此外，新興地區獲得醫療保健的機會有限以及缺乏全面的診斷設施也限制了市場的成長。創新研究領域包括探索基因療法、動脈修復的再生醫學，以及開發用於早期檢測和管理 PAD 的人工智慧技術。市場的性質是動態的，並受到技術進步和醫療保健政策變化的高度影響。為了確保永續的業務成長，公司正在優先考慮將治療創新與以患者為中心的護理模式相結合的適應性策略，並應考慮擴大服務欠缺地區的潛在合作關係。

主要市場統計
基準年[2023] 47.5億美元
預測年份 [2024] 51.4億美元
預測年份 [2030] 85.5億美元
複合年成長率（%） 8.73%

市場動態：快速發展的周邊動脈疾病治療市場的關鍵市場洞察

周邊動脈疾病藥物市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 隨著老年人口的增加，周邊動脈疾病的盛行率也隨之增加
    • 世界日益轉向不健康的生活方式
    • 對微創血管內治療的偏好日益增加
  • 市場限制因素
    • 治療周邊動脈疾病相關的高成本
  • 市場機會
    • 周邊動脈疾病先進治療方法的研究與開發
    • 周邊動脈疾病治療產品核可數量增加
  • 市場挑戰
    • 缺乏熟練周邊動脈疾病設備的專家和醫生

波特五力：駕馭周邊動脈疾病藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解周邊動脈疾病藥物市場的外部影響

外部宏觀環境因素在塑造周邊動脈疾病治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解周邊動脈疾病治療藥物市場的競爭狀況

周邊動脈疾病治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

周邊動脈疾病藥物市場供應商的 FPNV 定位矩陣績效評估

FPNV 定位矩陣是評估周邊動脈疾病藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃周邊動脈疾病治療藥物市場的成功之路

周邊動脈疾病治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 隨著人口老化的加劇，周邊動脈疾病的發生率也增加
      • 世界各地向不健康生活方式的轉變有所增加
      • 人們對微創血管內手術的興趣日益濃厚
    • 抑制因素
      • 治療周邊動脈疾病相關的高費用
    • 機會
      • 周邊動脈疾病先進治療方法的研究與開發
      • 治療周邊動脈疾病的藥物核准增加
    • 任務
      • 缺乏熟悉周邊動脈疾病設備的熟練專家和醫生
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的周邊動脈疾病治療藥物市場

  • 藥品
    • 抗高血壓藥
    • 草酸萘呋酯
    • 他汀類藥物
  • 手術治療
    • 血管成形術
    • 動脈繞道術

第7章依適應症階段周邊動脈疾病治療藥物市場

  • 無症狀
  • 缺血性休息痛
  • 輕度跛行
  • 中度/重度跛行
  • 潰瘍/壞疽

第8章周邊動脈疾病治療藥物市場：依最終用戶分類

  • 醫院
  • 專科診所

第9章北美及南美周邊動脈疾病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區周邊動脈疾病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲周邊動脈疾病治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Alucent Biomedical Inc.
  • AnGes, Inc.
  • AngioDynamics, Inc.
  • ARCA biopharma, Inc.
  • B. Braun SE
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cook Group Incorporated
  • Helixmith Co., Ltd.
  • Koninklijke Philips NV
  • LeMaitre Vascular, Inc.
  • Medtronic PLC
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • REVA Medical, LLC
  • Terumo Corporation
  • Venturis Therapeutics, Inc.
  • WL Gore & Associates, Inc.
Product Code: MRR-69324464D29D

The Peripheral Arterial Disease Therapeutics Market was valued at USD 4.75 billion in 2023, expected to reach USD 5.14 billion in 2024, and is projected to grow at a CAGR of 8.73%, to USD 8.55 billion by 2030.

The scope and definition of the Peripheral Arterial Disease (PAD) therapeutics market encompass the diagnosis, treatment, and management of PAD, a condition characterized by narrowed arteries reducing blood flow to the limbs. The necessity for effective PAD therapeutics arises from the increasing prevalence of risk factors like diabetes, hypertension, and obesity. Application areas include pharmaceuticals (e.g., anti-platelet drugs, statins), medical devices (stents, angioplasty balloons), and lifestyle management programs aimed at improving patient outcomes. End-use sectors primarily involve hospitals, specialty clinics, and home care settings. Market insights reveal that key factors driving growth include advancements in minimally invasive treatments, increasing awareness about PAD, and a surge in the geriatric population prone to vascular disorders. Recent opportunities are present in the development of drug-eluting technologies and biologics, as well as integrated healthcare solutions offering both medical intervention and digital monitoring of patients. To capitalize on these opportunities, companies should focus on R&D investments in personalized medicine and partnerships with tech firms for digital health solutions. Despite the promising growth, the market faces limitations such as high costs of advanced therapies, regulatory hurdles, and challenges in patient adherence to treatment regimens. Moreover, the market's growth is constrained by limited access to healthcare in emerging regions and a lack of comprehensive diagnostic facilities. Innovative research areas include the exploration of gene therapy, regenerative medicine for arterial repair, and the development of AI technologies for early PAD detection and management. The market nature is dynamic, heavily influenced by technological advancements and changing healthcare policies. To ensure sustained business growth, companies should prioritize adaptable strategies that couple treatment innovation with patient-centric care models and consider potential collaborations for expanding access in underserved regions.

KEY MARKET STATISTICS
Base Year [2023] USD 4.75 billion
Estimated Year [2024] USD 5.14 billion
Forecast Year [2030] USD 8.55 billion
CAGR (%) 8.73%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Peripheral Arterial Disease Therapeutics Market

The Peripheral Arterial Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of peripheral arterial disease with an increasing geriatric population
    • Increasing shift toward unhealthy lifestyles among people globally
    • Growing preference for minimally invasive endovascular procedures
  • Market Restraints
    • High cost associated with treatment of peripheral arterial disease
  • Market Opportunities
    • Research and development for advanced treatments for peripheral arterial disease
    • Growing product approvals for the treatment of peripheral arterial disease
  • Market Challenges
    • Lack of skilled professionals and doctors with proficiency in peripheral arterial disease devices

Porter's Five Forces: A Strategic Tool for Navigating the Peripheral Arterial Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Peripheral Arterial Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Peripheral Arterial Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Peripheral Arterial Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Peripheral Arterial Disease Therapeutics Market

A detailed market share analysis in the Peripheral Arterial Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Peripheral Arterial Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Peripheral Arterial Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Peripheral Arterial Disease Therapeutics Market

A strategic analysis of the Peripheral Arterial Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Peripheral Arterial Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alucent Biomedical Inc., AnGes, Inc., AngioDynamics, Inc., ARCA biopharma, Inc., B. Braun SE, Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cook Group Incorporated, Helixmith Co., Ltd., Koninklijke Philips N.V., LeMaitre Vascular, Inc., Medtronic PLC, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, REVA Medical, LLC, Terumo Corporation, Venturis Therapeutics, Inc., and W. L. Gore & Associates, Inc..

Market Segmentation & Coverage

This research report categorizes the Peripheral Arterial Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Medications and Surgical Treatments. The Medications is further studied across Antihypertensives, Naftidrofuryl Oxalate, and Statins. The Surgical Treatments is further studied across Angioplasty and Artery Bypass Graft.
  • Based on Indication Stage, market is studied across Asymptomatic, Ischemic Rest Pain, Mild Claudication, Moderate/Severe Claudication, and Ulcers/Gangrene.
  • Based on End-Users, market is studied across Hospitals and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of peripheral arterial disease with an increasing geriatric population
      • 5.1.1.2. Increasing shift toward unhealthy lifestyles among people globally
      • 5.1.1.3. Growing preference for minimally invasive endovascular procedures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with treatment of peripheral arterial disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Research and development for advanced treatments for peripheral arterial disease
      • 5.1.3.2. Growing product approvals for the treatment of peripheral arterial disease
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled professionals and doctors with proficiency in peripheral arterial disease devices
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Peripheral Arterial Disease Therapeutics Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medications
    • 6.2.1. Antihypertensives
    • 6.2.2. Naftidrofuryl Oxalate
    • 6.2.3. Statins
  • 6.3. Surgical Treatments
    • 6.3.1. Angioplasty
    • 6.3.2. Artery Bypass Graft

7. Peripheral Arterial Disease Therapeutics Market, by Indication Stage

  • 7.1. Introduction
  • 7.2. Asymptomatic
  • 7.3. Ischemic Rest Pain
  • 7.4. Mild Claudication
  • 7.5. Moderate/Severe Claudication
  • 7.6. Ulcers/Gangrene

8. Peripheral Arterial Disease Therapeutics Market, by End-Users

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Specialty Clinics

9. Americas Peripheral Arterial Disease Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Peripheral Arterial Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Peripheral Arterial Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alucent Biomedical Inc.
  • 3. AnGes, Inc.
  • 4. AngioDynamics, Inc.
  • 5. ARCA biopharma, Inc.
  • 6. B. Braun SE
  • 7. Becton, Dickinson and Company
  • 8. BIOTRONIK SE & Co. KG
  • 9. Boston Scientific Corporation
  • 10. Cook Group Incorporated
  • 11. Helixmith Co., Ltd.
  • 12. Koninklijke Philips N.V.
  • 13. LeMaitre Vascular, Inc.
  • 14. Medtronic PLC
  • 15. Meril Life Sciences Pvt. Ltd.
  • 16. MicroPort Scientific Corporation
  • 17. REVA Medical, LLC
  • 18. Terumo Corporation
  • 19. Venturis Therapeutics, Inc.
  • 20. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY NAFTIDROFURYL OXALATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ARTERY BYPASS GRAFT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASYMPTOMATIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ISCHEMIC REST PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MILD CLAUDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MODERATE/SEVERE CLAUDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ULCERS/GANGRENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 235. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023